Shuganjianpi France And The Drugs For Treatment Of Fatty Liver Clinical Research

Objectives: To observe therapeutic effect of the smoothing liver and invigorating spleen treatment and its typical recipe on fatty liver, to objectively estimate its effect and security on treating fatty liver, and to search for reliable and safe TCM treatment and herbs treating fatty liver.Methods: sisty cases of patients with fatty liver detected in health care medical examination were chosen, all of them were incumbent cadres with high fat and high calories diet, usually drinking lots of alcohol and taking less than one hour's exercise a week. According to the clinical diagnostic criteria of AFL: there arel 6 cases of AFLD and 44 cases of NAFLD. Patients were randomly divided into 2 groups: treatment group (n=35, 9 cases of AFLD and 26 cases of NAFLD) and control group (n=25, 7 cases of AFLD and 18 cases of NAFLD). The treatment group took a dose of decocted shuganjianpifang everyday (chaihushugansan and shenlin baizhusan), the control group took dongbaogantai troche(3 pills a time, 3 times a day).We made a observation of the amelioration of the symptoms of these two groups patients. Liver function, serum lipid, blood sugar and the morphologic B ultrasonic changes of liver were counterchecked every month. Treatment cycle was 3 months. Drugs that potentially affect liver function and serum lipid were not allowed during observation period. Results: For the treatment group, the total effect ratio were 100%, 26 cases were healed, accounting for 74%; 7 cases were distinctly effective, accounting for 20%; 2 cases were effective, accounting for 6%. For the control group, the total effect ratio were 96% and excellence rate of curing is 80%, 12 cases were healed, accounting for 48%, 8 cases were distinctly effective, accounting for 32%; 4 cases were effective, accounting for 16%; 1 cases was noneffective, accounting for 4%. The effect ratio of the treatment group was higher than the control group's.Conclusions:Three-month course observation of the study showed: in the overall efficacy, changes happened in main indicators such as condition score, aminotransferase, lipids and 3 items of liver fibrosis in both two groups, suggesting liver protection and lipid-lowering effects of the two treatment methods were ideal. There were no significant difference between treatment group and control group (p＞0.05). However, in the clinical cure rate, significant difference existed between the two groups. (p＜0.05). Therapy in the treatment group can not only significantly improve the clinical signs and symptoms and reduce the severity of liver B ultrasound, but also can be economic and security, worthy of widely clinical use.